Nachrichten zur Wave Life Sciences Ltd. Aktie

WVE Stock Soars on Upbeat Initial Antitrypsin Deficiency Study Data

Wave Life Sciences stock soars on positive initial data showing the first-ever therapeutic RNA editing in humans in the phase…

Wave Life Sciences to Present at Chardan 8th Annual Genetic Medicines Conference

CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company…

Wave Life Sciences Prices Upsized $200 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

CAMBRIDGE, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company…

Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants

CAMBRIDGE, Mass., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company…

Wave Life Sciences: Spiking On Strong DMD Data, But Not Fully De-Risked Yet

…

Wave Life Sciences Ltd. (WVE) Q2 2024 Earnings Call Transcript

…

Wave Life Sciences Weighty Ambition: Carving Out Obesity Niche

…

RBC maintains $5 target on WAVE Life Sciences shares By Investing.com

RBC maintains $5 target on WAVE Life Sciences shares…

Wave Life Sciences Ltd. (WVE) Q4 2023 Earnings Call Transcript

…

Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024

CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company…

Wave Life Sciences to Present at 42nd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines…

Wave Life Sciences: What To Make Of The Discounted Offering

…

: Wave Life Sciences stock slides 31% after company prices $100 million secondary share offering

Wave Life Sciences Ltd.’s stock WVE tumbled 31% Thursday, after the clinical-stage pharma company priced a $100 million secondary share…

Wave Life Sciences Ltd. (WVE) Q3 2023 Earnings Call Transcript

…

Wave Life Sciences Q3 2023 Earnings Preview

…

Wave Life Sciences Third Quarter 2023 Financial Results Scheduled for November 9, 2023

CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines…

Huntingtons Disease Market to Witness Upsurge in Growth by 2032, Predicts DelveInsight | Key Companies to Watch Out - Prilenia, Neurocrine, Annexon, SOM, Vaccinex, Sage, UniQure, Wave life sciences, Takeda, Medesis

The growth of the Huntington’s disease market is expected to be mainly driven by entry of innovative emerging therapies, rising…

Wave Life Sciences spikes on R&D Day

…

Wave Life Sciences to Present at the Chardan 7th Annual Genetic Medicines Conference

CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines…

Form 10-Q Wave Life Sciences Ltd. For: Jun 30

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Wave Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update

Preparing for imminent submission of clinical trial applications (CTAs) for GalNAc-conjugated AATD candidate (WVE-006), the industrys first RNA editing clinical candidate...…

Wave Life Sciences Second Quarter 2023 Financial Results Scheduled for August 3, 2023

CAMBRIDGE, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines…

Wave Life Sciences an outperform at Raymond James on RNA editing

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Wave Life Sciences started at outperform with $7 stock price target at Raymond James

Um den gesamten Artikel unter marketwatch.com zu lesen, klicken Sie bitte auf die Überschrift...…

Wave Life Sciences Joins the Russell 2000® and Russell 3000® Indexes

CAMBRIDGE, Mass., June 26, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines…

XFRA : 1U5: Wiederaufnahme/Resumption

FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING…

XFRA : 1U5: Aussetzung/Suspension

DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME …

Wave Life Sciences crashes on decision to drop neurology asset on trial setback

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Wave Life Sciences Ends Development of WVE-004 to Treat Lou Gehrigs Disease, Dementia

Wave Life Sciences Ends Development of WVE-004 to Treat Lou Gehrig's Disease, Dementia...…

Form 8-K Wave Life Sciences Ltd. For: May 23

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

XFRA : INSTRUMENT_SUSPENSION - SG9999014716

Instrument ID [7692] (1U5 - SG9999014716) suspended...…

Wave Life Sciences Announces Topline Results from Phase 1b/2a FOCUS-C9 Study of WVE-004 for C9orf72-associated Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

Potent and durable target engagement observed across cohorts, including with 10 mg doses administered every 12 weeks which were also…

dpa-AFX ProFeed